EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Periprocedural Pulmonary Hypertension and Outcomes After Mitral Valve Transcatheter Edge-to-Edge Repair

Junichi Miyamoto, Yohei Ohno, Satoshi Noda, Norihiko Kamioka, Tsutomu Murakami, Yuji Ikari, Shunsuke Kubo, Yuki Izumi, Mike Saji, Masanori Yamamoto, Atsushi Sugiura, Tetsuro Shimura und 18 weitere

JACC: Cardiovascular Interventions · 2026

DOI: 10.1016/j.jcin.2026.08.017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026. Verfasst von Junichi Miyamoto und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tokai University, Isehara, Japan. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Hypertension, Pulmonary, Cardiac Catheterization, Mitral Valve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Boston Scientific Japan, Daiichi Sankyo Kabushiki Kaisha, Edwards Lifesciences Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pulmonary hypertension (PH) is common in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER), but the prognostic significance of periprocedural PH changes remains uncertain. OBJECTIVES: This study sought to evaluate the association between periprocedural PH patterns and clinical outcomes after M-TEER and to identify predictors of residual and new-onset PH. METHODS: The OCEAN-Mitral registry prospectively enrolled 3,764 patients with severe mitral regurgitation treated with M-TEER. Among 3,484 patients with paired echocardiographic tricuspid regurgitation pressure gradient (TRPG) data, PH was defined as TRPG >31 mm Hg. Patients were classified as having no PH, normalized PH, new-onset PH, or residual PH according to pre- and postprocedural PH status. The primary endpoint was 2-year cardiovascular death or heart failure hospitalization. Multivariable logistic regression identified predictors of residual and new-onset PH. RESULTS: No PH was observed in 1,432 patients (41.1%), normalized PH in 763 (21.9%), new-onset PH in 298 (8.6%), and residual PH in 991 (28.4%). The 2-year incidence of the primary endpoint differed significantly across groups (17.6%, 18.1%, 27.2%, and 27.6%, respectively; P 50 mm Hg, and tricuspid annular dilation predicted residual PH, whereas residual mitral regurgitation and postprocedural transmitral gradients >5 mm Hg predicted new-onset PH. CONCLUSIONS: Periprocedural PH dynamics provide robust risk stratification after M-TEER, identifying low-risk patients with PH normalization and high-risk subsets with residual or new-onset PH, requiring closer surveillance and procedural optimization. Registration Treatment and Prognosis of Heart Valve Registry; UMIN-ID: UMIN000023653.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHypertension, PulmonaryCardiac CatheterizationMitral ValveHeart Valve Prosthesis ImplantationHumansFemaleRegistriesTime FactorsMaleRisk FactorsAgedTreatment OutcomeSeverity of Illness IndexProspective StudiesAged, 80 and overRecovery of FunctionRisk Assessment

Stichwörter der Autor:innen

mitral regurgitation (MR)mitral valve (MV)pulmonary hypertension (PH)transcatheter edge-to-edge repair

Autor:innen und Institutionen

  • Department of Cardiology, Tokai University, Isehara, Japan.
  • Department of Cardiology, Tokai University, Isehara, Japan. Electronic address: yohei_ohno@hotmail.com.
  • Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
  • Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan; Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine, Tokyo, Japan.
  • Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.

Förderung

  • Boston Scientific Japan
  • Daiichi Sankyo Kabushiki Kaisha
  • Edwards Lifesciences Corporation
  • Medtronic Japan Co Ltd
  • Abbott Japan Godo Kaisha

Zitieren

APA

Miyamoto, J., Ohno, Y., Noda, S., Kamioka, N., Murakami, T., Ikari, Y., Kubo, S., Izumi, Y., Saji, M., Yamamoto, M., Sugiura, A., Shimura, T., Asami, M., Enta, Y., Shirai, S., Izumo, M., Mizuno, S., Watanabe, Y., Amaki, M., …, & OCEAN-Mitral Investigators (2026). Periprocedural Pulmonary Hypertension and Outcomes After Mitral Valve Transcatheter Edge-to-Edge Repair. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2026.08.017

Vancouver

Miyamoto J, Ohno Y, Noda S, Kamioka N, Murakami T, Ikari Y, et al. Periprocedural Pulmonary Hypertension and Outcomes After Mitral Valve Transcatheter Edge-to-Edge Repair. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2026.08.017

BibTeX
@article{Miyamoto2026,
  author = {Miyamoto, Junichi and Ohno, Yohei and Noda, Satoshi and Kamioka, Norihiko and Murakami, Tsutomu and Ikari, Yuji and Kubo, Shunsuke and Izumi, Yuki and Saji, Mike and Yamamoto, Masanori and Sugiura, Atsushi and Shimura, Tetsuro and Asami, Masahiko and Enta, Yusuke and Shirai, Shinichi and Izumo, Masaki and Mizuno, Shingo and Watanabe, Yusuke and Amaki, Makoto and Kodama, Kazuhisa and Otsuki, Hisao and Naganuma, Toru and Bota, Hiroki and Yamawaki, Masahiro and Ueno, Hiroshi and Nakazawa, Gaku and Hachinohe, Daisuke and Otsuka, Toshiaki and Hayashida, Kentaro and OCEAN-Mitral Investigators, OCEAN-Mitral Investigators},
  title = {Periprocedural Pulmonary Hypertension and Outcomes After Mitral Valve Transcatheter Edge-to-Edge Repair},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1016/j.jcin.2026.08.017}
}
Kostenlos starten →